Emetant 40 mg (Capsule)
Unit Price: ৳ 45.00 (1 x 10: ৳ 450.00)
Strip Price: ৳ 450.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Aprepitant |
| Company | Biogen pharmaceuticals ltd |
Indications
- Prevention of postoperative nausea and vomiting (PONV)
- Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)
Pharmacology
Aprepitant is a selective high affinity antagonist of human substance P neurokinin 1 (NK1) receptors.
Dosage
- Post Operative Nausea and Vomiting: 40 mg within 3 hours prior to induction of anesthesia
- Chemotherapy-Induced Nausea and Vomiting:
- Regimen for highly emetogenic cancer chemotherapy:
- Day 1: Aprepitant 125 mg orally, Dexamethasone 12 mg orally, 5-HT3 antagonist (Ondansetron): 24 mg 30 minutes before the start of chemotherapy
- Day 2: Aprepitant 80 mg orally, Dexamethasone 8 mg orally
- Day 3: Aprepitant 80 mg orally, Dexamethasone 8 mg orally
- Day 4: Dexamethasone 8 mg orally
- Regimen for moderately emetogenic cancer chemotherapy:
- Day 1: Aprepitant 125 mg orally, Dexamethasone 12 mg orally, 5-HT3 antagonist (Ondansetron): one 8 mg tablet 30 minutes before chemotherapy followed by an 8 mg dose 8 hours later
- Day 2: Aprepitant 80 mg orally, 5-HT3 antagonist (Ondansetron): 8 mg tablet twice a day
- Day 3: Aprepitant 80 mg orally, 5-HT3 antagonist (Ondansetron): 8 mg tablet twice a day
- Regimen for highly emetogenic cancer chemotherapy:
Administration
May be taken with or without food. No dosage adjustment is necessary for the elderly patients.
Interaction
Emetant is a substrate, a weak-to-moderate (dose dependent) inhibitor, and an inducer of CYP3A4.
Contraindications
Contraindicated in patients who are hypersensitive to any component of the product. Should not be used concurrently with Pimozide, Terfenadine, Astemizole & Cisapride.
Side Effects
- Constipation
- Hypotension
- Pruritus
- Pyrexia
Pregnancy & Lactation
Pregnancy Category B. This drug should be used during pregnancy only if clearly needed.
Use in Special Populations
- Patients with Renal Impairment: No dosage adjustment is necessary for patients with renal impairment or for patients with end-stage renal disease (ESRD) undergoing hemodialysis.
- Patients with Hepatic Impairment: No dosage adjustment is necessary for patients with mild to moderate hepatic impairment.
Overdose Effects
No specific information is available on the treatment of overdosage with Emetant.
Therapeutic Class
Anti-emetic drugs
Storage Conditions
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.